NTRANatera, Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is NTRA?
Natera, Inc. earns −28% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 37 points below what the capital costs: growth destroys value
- Operating margin
- −11%
Operating margin · Diagnostics & Research median 3.6% · 12 months to Q2 2026
- Share count, year on year
- +5.1%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 29%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −55% |
| FY2021 | −75% |
| FY2022 | −66% |
| FY2023 | −41% |
| FY2024 | −13% |
| FY2025 | −13% |
Details›
- Operating margin12 months to Q2 2026
- −11%
- Net margin12 months to Q2 2026
- −7.1%
- Free cash flow margin
- 3.1%
- R&D as % of revenue
- 29%
- Revenue, trailing twelve months
- $2.71B
- Free cash flow, trailing twelve months
- $84M
- Net income, trailing twelve months
- −$192M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −28%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Diagnostics & Research
Ranks #12 of 21 by RyuScore